Keywords
How to Cite
Abstract
Objectives: To identify the main reasons and exchange strategies for biological therapies in patients with rheumatoid arthritis (RA) treated at a Biological Medicines Infusion Center at a University Hospital in Northeastern Brazil. Methods: A cross-sectional study was carried out with retrospective data collection in a sample of patients registered in the Unified Health System, who had biological replacement during the treatment. We collected data on pharmaceutical monitoring and medical records, clinical and demographic parameters, as well as reason, strategy and replacement time for each biological therapy. Results: Women made up the majority of the sample, with a mean age of 51.6 years. There were 258 substitutions between biological products, ranging from one to four substitutions per patient. Anti-TNFα agents were the most prescribed class, with infliximab being the most frequent (39.9%). In 58.2% of the cases, after the suspension of the first, a new anti-TNFα was chosen. The first substitution of treatment occurred mainly from one monoclonal antibody to another. Most substitutions were due to secondary failure, followed by adverse events. Conclusion: The study allowed to outline the causes for the replacement of biological therapy in patients with rheumatoid arthritis.
Todo o conteúdo dos artigos publicados no JAFF está licenciado sob uma Licença Creative Commons Atribuição 4.0 Internacional, que permite o uso, compartilhamento, adaptação, distribuição e reprodução em qualquer meio ou formato, desde que você dê o devido crédito ao autor(es) original(ais) e a fonte, fornecer um link para a licença Creative Commons e indicar se alterações foram feitas. As imagens ou outros materiais de terceiros neste artigo estão incluídos na licença Creative Commons do artigo, salvo indicação em contrário em uma linha de crédito para o material.